- According to Market Research Intellect from the MRI Team, Vinorelbine Tartrate injection is projected to expand at a compound annual growth rate (CAGR) of 9.33% between 2024 and 2031
- By 2024, the market is projected to reach USD 25.32 billion
- By 2031, the valuation is anticipated to reach USD 47.27 billion
Vinorelbine is an anti-mitotic chemotherapy medication used to treat a variety of cancers, such as breast cancer and non-small cell lung cancer (NSCLC) 5. It was first licensed in the United States in the 1990s to treat NSCLC 13.
Adults with advanced non-small cell lung cancer (NSCLC) may receive vinorelbine tartrate as a single treatment or in conjunction with other chemotherapy medications.
More specifically, it has been used with methotrexate to treat aggressive fibromatosis or relapsed or refractory Hodgkin lymphoma. It has also been combined with other chemotherapeutic drugs to treat desmoid tumours.
In patients who have previously received anthracyline and/or taxane therapy, vinorelbine tartrate has also been used to treat recurrent or metastatic ovarian cancer, metastatic breast cancer, and recurrent or metastatic squamous cell head and neck cancer.
Furthermore, the medication has been used in conjunction with trastuzumab and everolimus to treat HER2-positive, trastuzumab-resistant, advanced breast cancer in patients who have already received taxane treatment.
Download GMP-Certified API Product List
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations. Click here to download our complete API product list.
Get your requested raw materials quotation
Table of Contents
The market is expected to reach USD 47.27 Billion by 2031
The global market for Vinorelbine Tartrate injection is projected to expand at a compound annual growth rate (CAGR) of 9.33% between 2024 and 2031, according to Market Research Intellect from the MRI Team. By 2024, the market is projected to reach USD 25.32 billion. By 2031, the valuation is anticipated to reach USD 47.27 billion.
Get your requested raw materials quotation
Improved formulations and increasing investments in cancer research behind the market expansion
The market for vinorelbine tartrate injection is growing rapidly since it is a necessary treatment for some malignancies, such as breast and non-small cell lung cancer. The increasing incidence of cancer and advances in oncology have led to a strong demand for powerful chemotherapy medications like Vinorelbine Tartrate.
Further propelling the market’s expansion are improved formulations and more investments in cancer research. The increasing usage of vinorelbine tartrate injections is a sign of a broader trend towards better cancer care and treatment results. An increase in cancer medication availability and awareness on a worldwide scale also supports this.
The need for effective treatment alternatives and the rising prevalence of cancer are two factors driving the vinorelbine tartrate injection market. The medication’s proven ability to treat a range of cancers and ongoing research into its therapeutic potential promote the market’s growth.
Advances in pharmaceutical delivery technology and vinorelbine formulations are also driving demand.
Additionally, facilitating global access to healthcare services and cancer treatment also aids in market expansion. Important aspects propelling the Vinorelbine Tartrate injection market include the objective of improving cancer care and treatment outcomes as well as supportive healthcare legislation.
Focus on Improved Drug Delivery Systems
It is anticipated that Vinorelbine Tartrate Injections with improved drug delivery systems will take over the market. This might involve developments in encapsulating technologies like liposomes, which offer individualised drug delivery and possibly minimise adverse effects. It is projected that market expansion will be driven by research and development projects targeted at lowering Vinorelbine Tartrate’s cytotoxicity, or its potential to damage healthy cells.
Rise of Generic Manufacturers Will Bring Down The Cost
As generic manufacturers appear, the market for Vinorelbine Tartrate injection might get more competitive. Generic substitutes are anticipated to hit the market after the drug’s patents expire, potentially bringing down overall pharmaceutical costs. Vinorelbine tartrate injection treatment may become more accessible to patients as a result of this trend towards affordability, particularly in places with constrained healthcare resources.
Want to buy GMP API pharmaceutical ingredients?
MedicaPharma ensures access to GMP active pharmaceutical ingredients across multiple resilient global supply chains. Click here to view a full GMP API product list.
MedicaPharma is capable of supplying all GMP materials needed; our experience with sourcing materials that are difficult to obtain makes us the ultimate choice; just challenge us, and we will find any material you need.
Get a Fast and Easy GMP-Certified API Quote
Focus on your compounding pharmacy business and let MedicaPharma take care of your APIs. Obtaining a quote is easy
